Compare PFBC & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFBC | SDGR |
|---|---|---|
| Founded | 1991 | 1990 |
| Country | United States | United States |
| Employees | 324 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | N/A | 2020 |
| Metric | PFBC | SDGR |
|---|---|---|
| Price | $105.41 | $23.17 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $102.67 | $21.00 |
| AVG Volume (30 Days) | 67.8K | ★ 876.6K |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.41% | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $255,869,000.00 |
| Revenue This Year | $2.94 | $0.76 |
| Revenue Next Year | $8.31 | $4.60 |
| P/E Ratio | $8.85 | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $81.50 | $10.95 |
| 52 Week High | $112.26 | $23.02 |
| Indicator | PFBC | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 61.45 |
| Support Level | $103.06 | $17.23 |
| Resistance Level | $105.95 | $21.40 |
| Average True Range (ATR) | 2.00 | 1.05 |
| MACD | 0.09 | -0.15 |
| Stochastic Oscillator | 83.03 | 76.53 |
Preferred Bank is a commercial bank located in California. Its products and services are divided into Personal Banking, Business Banking, and Commercial Banking, which include Checking accounts, Savings accounts, CDs, Loans and Credit, Electronic banking, and Treasury Management. It provides personalized deposit services, real estate finance, commercial loans, and trade finance credit facilities to small and mid-sized businesses and their owners, entrepreneurs, real estate developers and investors, professionals, and high-net-worth individuals.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.